目的 匯總同煤集團總醫(yī)院腫瘤內(nèi)科鉑類抗腫瘤藥物的使用情況，對化療過程中可能出現(xiàn)的不良反應進行分析，促進臨床合理、安全用藥。方法 收集2016年10月—2017年10月同煤集團總醫(yī)院腫瘤內(nèi)科所有鉑類藥物不良反應的報告，并對藥物基本使用情況與患者用藥信息進行記錄和分析。結(jié)果 共有943例患者使用鉑類藥物，發(fā)生不良反應458例，不良反應發(fā)生率為48.57%。鉑類藥物不良反應在中年女性中發(fā)生率較高，肺癌患者最多，占35.59%。不良反應主要表現(xiàn)為血液系統(tǒng)毒性、胃腸道毒性、神經(jīng)系統(tǒng)毒性。98.03%患者不良反應預后良好。結(jié)論 臨床藥師應當密切關注鉑類化療藥物的不良反應，預防不良反應的發(fā)生，降低不良反應的發(fā)生率，保障腫瘤患者用藥安全。

Objective To summarize the usage situation of platinum anti-tumor drugs in Department of Medical Oncology in General Hospital of Datong Coal Group, and to analyze the possible adverse reactions in the course of chemotherapy, and to promote the rational and safety medication in clinic. Methods The reports of adverse reactions of induced by platinum drugs in Department of Medical Oncology General Hospital of Datong Coal Group from October 2016 to October 2017 were collected, and the basic usage situation of drugs and the patient's medication information were recorded and analyzed. Results Patients (943 cases) used platinum drugs, while there were 458 cases of adverse reactions, and the rate was 48.57%. Middle-aged women had higher incidence of adverse reactions. And more were patients with lung cancer, and the incidence of adverse reactions was 35.59%. The main performances of adverse reactions were blood system toxicity, gastrointestinal system toxicity, and nerve system toxicity. The prognosis of 98.03% patients was favorable. Conclusion Clinical pharmacists should pay close attention to the adverse reactions of platinum chemotherapy drugs, prevent the occurrence of adverse reactions, reduce the incidence of adverse reactions, and ensure the safety medication in cancer patients.